25 XP   0   0   10

XBiotech Inc
Buy, Hold or Sell?

Let's analyse Xbiotech together

PenkeI guess you are interested in XBiotech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of XBiotech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about XBiotech Inc

I send you an email if I find something interesting about XBiotech Inc.

Quick analysis of Xbiotech (30 sec.)










What can you expect buying and holding a share of Xbiotech? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.2%

What is your share worth?

Current worth
$7.19
Expected worth in 1 year
$6.48
How sure are you?
31.7%

+ What do you gain per year?

Total Gains per Share
$-0.71
Return On Investment
-8.7%

For what price can you sell your share?

Current Price per Share
$8.13
Expected price per share
$6.12 - $9.1
How sure are you?
50%

1. Valuation of Xbiotech (5 min.)




Live pricePrice per Share (EOD)

$8.13

Intrinsic Value Per Share

$-6.36 - $2.29

Total Value Per Share

$0.83 - $9.47

2. Growth of Xbiotech (5 min.)




Is Xbiotech growing?

Current yearPrevious yearGrowGrow %
How rich?$218.8m$251.6m-$24.7m-10.9%

How much money is Xbiotech making?

Current yearPrevious yearGrowGrow %
Making money-$6.1m-$8.2m$2m34.0%
Net Profit Margin0.0%-915.3%--

How much money comes from the company's main activities?

3. Financial Health of Xbiotech (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#245 / 1031

Most Revenue
#820 / 1031

Most Profit
#498 / 1031

Most Efficient
#273 / 1031

What can you expect buying and holding a share of Xbiotech? (5 min.)

Welcome investor! Xbiotech's management wants to use your money to grow the business. In return you get a share of Xbiotech.

What can you expect buying and holding a share of Xbiotech?

First you should know what it really means to hold a share of Xbiotech. And how you can make/lose money.

Speculation

The Price per Share of Xbiotech is $8.13. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xbiotech.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xbiotech, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.19. Based on the TTM, the Book Value Change Per Share is $-0.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xbiotech.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-1.9%-0.20-2.5%-0.27-3.3%0.789.6%0.243.0%
Usd Book Value Change Per Share-0.13-1.5%-0.18-2.2%-0.24-2.9%0.303.7%0.172.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.627.6%0.303.7%
Usd Total Gains Per Share-0.13-1.5%-0.18-2.2%-0.24-2.9%0.9211.3%0.475.8%
Usd Price Per Share4.00-4.38-5.35-10.18-8.61-
Price to Earnings Ratio-6.57--5.72--6.60--360.56--179.28-
Price-to-Total Gains Ratio-31.94--26.16--30.16-28.84-5.57-
Price to Book Ratio0.56-0.59-0.64-1.91-2.51-
Price-to-Total Gains Ratio-31.94--26.16--30.16-28.84-5.57-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.13
Number of shares123
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.62
Usd Book Value Change Per Share-0.180.30
Usd Total Gains Per Share-0.180.92
Gains per Quarter (123 shares)-21.77112.86
Gains per Year (123 shares)-87.07451.45
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-87-97303148441
20-174-184606297892
30-261-2719094451343
40-348-35812125941794
50-435-44515157422245
60-522-53218188912696
70-609-619212110393147
80-697-706242411883598
90-784-793272713364049
100-871-880303014854500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.040.00.02.4%1.041.00.02.4%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%6.014.00.030.0%10.028.03.024.4%11.028.03.026.2%
Dividend per Share0.00.04.00.0%4.00.08.033.3%5.00.015.025.0%5.00.036.012.2%5.00.037.011.9%
Total Gains per Share0.04.00.00.0%4.08.00.033.3%9.011.00.045.0%13.025.03.031.7%14.025.03.033.3%

Fundamentals of Xbiotech

About XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Fundamental data was last updated by Penke on 2024-03-22 08:10:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of XBiotech Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xbiotech earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of XBiotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-915.3%+915.3%
TTM-5Y-207.3%+207.3%
5Y-207.3%10Y-101.1%-106.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM--202.3%+202.3%
YOY-915.3%-263.0%-652.3%
5Y-207.3%-452.4%+245.1%
10Y-101.1%-589.0%+487.9%
1.1.2. Return on Assets

Shows how efficient Xbiotech is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • -2.0% Return on Assets means that Xbiotech generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of XBiotech Inc:

  • The MRQ is -2.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.0%TTM-2.6%+0.6%
TTM-2.6%YOY-3.2%+0.5%
TTM-2.6%5Y1.0%-3.6%
5Y1.0%10Y-7.3%+8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.0%-12.5%+10.5%
TTM-2.6%-12.2%+9.6%
YOY-3.2%-11.2%+8.0%
5Y1.0%-13.3%+14.3%
10Y-7.3%-14.6%+7.3%
1.1.3. Return on Equity

Shows how efficient Xbiotech is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • -2.1% Return on Equity means Xbiotech generated $-0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of XBiotech Inc:

  • The MRQ is -2.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.1%TTM-2.7%+0.6%
TTM-2.7%YOY-3.3%+0.6%
TTM-2.7%5Y1.2%-3.9%
5Y1.2%10Y-7.9%+9.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.1%-16.0%+13.9%
TTM-2.7%-15.8%+13.1%
YOY-3.3%-13.9%+10.6%
5Y1.2%-18.2%+19.4%
10Y-7.9%-19.1%+11.2%

1.2. Operating Efficiency of XBiotech Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xbiotech is operating .

  • Measures how much profit Xbiotech makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of XBiotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1,365.1%+1,365.1%
TTM-5Y-312.6%+312.6%
5Y-312.6%10Y-152.5%-160.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM--208.5%+208.5%
YOY-1,365.1%-280.2%-1,084.9%
5Y-312.6%-459.9%+147.3%
10Y-152.5%-596.9%+444.4%
1.2.2. Operating Ratio

Measures how efficient Xbiotech is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of XBiotech Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY14.651-14.651
TTM-5Y3.704-3.704
5Y3.70410Y1.807+1.897
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM-3.181-3.181
YOY14.6513.609+11.042
5Y3.7045.554-1.850
10Y1.8077.396-5.589

1.3. Liquidity of XBiotech Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xbiotech is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 33.07 means the company has $33.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of XBiotech Inc:

  • The MRQ is 33.069. The company is very able to pay all its short-term debts. +2
  • The TTM is 44.635. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ33.069TTM44.635-11.566
TTM44.635YOY57.389-12.754
TTM44.6355Y48.476-3.841
5Y48.47610Y29.512+18.964
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ33.0693.987+29.082
TTM44.6354.440+40.195
YOY57.3895.569+51.820
5Y48.4766.158+42.318
10Y29.5126.492+23.020
1.3.2. Quick Ratio

Measures if Xbiotech is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • A Quick Ratio of 32.94 means the company can pay off $32.94 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of XBiotech Inc:

  • The MRQ is 32.944. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 52.067. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ32.944TTM52.067-19.123
TTM52.067YOY65.096-13.029
TTM52.0675Y49.850+2.217
5Y49.85010Y29.959+19.891
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ32.9443.653+29.291
TTM52.0674.158+47.909
YOY65.0965.515+59.581
5Y49.8506.012+43.838
10Y29.9596.206+23.753

1.4. Solvency of XBiotech Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xbiotech assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xbiotech to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Xbiotech assets are financed with 3.7% credit (debt) and the remaining percentage (100% - 3.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of XBiotech Inc:

  • The MRQ is 0.037. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.029. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.037TTM0.029+0.008
TTM0.029YOY0.027+0.002
TTM0.0295Y0.030-0.002
5Y0.03010Y0.048-0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0370.336-0.299
TTM0.0290.330-0.301
YOY0.0270.267-0.240
5Y0.0300.367-0.337
10Y0.0480.378-0.330
1.4.2. Debt to Equity Ratio

Measures if Xbiotech is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • A Debt to Equity ratio of 3.8% means that company has $0.04 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of XBiotech Inc:

  • The MRQ is 0.038. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.030. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.038TTM0.030+0.009
TTM0.030YOY0.027+0.002
TTM0.0305Y0.032-0.002
5Y0.03210Y0.052-0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0380.376-0.338
TTM0.0300.398-0.368
YOY0.0270.334-0.307
5Y0.0320.431-0.399
10Y0.0520.476-0.424

2. Market Valuation of XBiotech Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Xbiotech generates.

  • Above 15 is considered overpriced but always compare Xbiotech to the Biotechnology industry mean.
  • A PE ratio of -6.57 means the investor is paying $-6.57 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of XBiotech Inc:

  • The EOD is -13.353. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.570. Based on the earnings, the company is expensive. -2
  • The TTM is -5.721. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.353MRQ-6.570-6.783
MRQ-6.570TTM-5.721-0.849
TTM-5.721YOY-6.598+0.877
TTM-5.7215Y-360.564+354.843
5Y-360.56410Y-179.282-181.282
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.353-2.697-10.656
MRQ-6.570-2.422-4.148
TTM-5.721-2.709-3.012
YOY-6.598-4.116-2.482
5Y-360.564-6.257-354.307
10Y-179.282-6.478-172.804
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of XBiotech Inc:

  • The EOD is -17.444. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.583. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.896. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.444MRQ-8.583-8.861
MRQ-8.583TTM-9.896+1.314
TTM-9.896YOY-3.277-6.619
TTM-9.8965Y-6.870-3.027
5Y-6.87010Y-6.537-0.333
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-17.444-3.344-14.100
MRQ-8.583-2.939-5.644
TTM-9.896-3.486-6.410
YOY-3.277-5.592+2.315
5Y-6.870-8.464+1.594
10Y-6.537-8.872+2.335
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xbiotech is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.56 means the investor is paying $0.56 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of XBiotech Inc:

  • The EOD is 1.131. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.557. Based on the equity, the company is cheap. +2
  • The TTM is 0.588. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.131MRQ0.557+0.575
MRQ0.557TTM0.588-0.032
TTM0.588YOY0.639-0.051
TTM0.5885Y1.913-1.325
5Y1.91310Y2.506-0.593
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1312.198-1.067
MRQ0.5572.042-1.485
TTM0.5882.121-1.533
YOY0.6392.907-2.268
5Y1.9133.682-1.769
10Y2.5064.114-1.608
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of XBiotech Inc.

3.1. Institutions holding XBiotech Inc

Institutions are holding 15.153% of the shares of XBiotech Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc2.89620.000188151190681.0394
2023-12-31Millennium Management LLC2.61430.0014795726-135718-14.5707
2023-12-31BlackRock Inc0.91390278159-676-0.2424
2023-12-31Credit Suisse First Boston (CSFB)0.81570.00124827030001.2231
2023-12-31Geode Capital Management, LLC0.63270.000119258898505.3902
2023-12-31Bridgeway Capital Management, LLC0.47510.012414459353523.8437
2023-12-31Morgan Stanley - Brokerage Accounts0.363101105172329026.7004
2023-12-31Northern Trust Corp0.25960.0001790272627949.8199
2023-12-31Dimensional Fund Advisors, Inc.0.23810.00017247500
2023-12-31Connor Clark & Lunn Inv Mgmt Ltd0.21010.001263945-373-0.5799
2023-12-31Empowered Funds, LLC0.19570.0065955253529.8745
2023-12-31Man Group PLC0.19170.00075835543598.0728
2023-12-31State Street Corporation0.185705652600
2023-12-31Qube Research & Technologies0.18560.000456477539172106.1328
2023-12-31Bank of New York Mellon Corp0.1830.00015569300
2023-12-31Susquehanna International Group, LLP0.123037446-3583-8.7328
2023-12-31Two Sigma Investments LLC0.08360.000225440-5400-17.5097
2023-12-31Two Sigma Advisers, LLC0.07890.000224000-5200-17.8082
2023-12-31FMR Inc0.065802004000
2023-12-31Squarepoint Ops LLC0.06220.000118922189220
Total 10.7740.02413279262+8439+0.3%

3.2. Funds holding XBiotech Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Total Stock Mkt Idx Inv2.04540.000262254600
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.76740.001123357122000.9509
2023-12-31Fidelity Extended Market Index0.36110.001210992375197.3425
2023-09-30Bridgeway Ultra-Small Company0.21370.36665041814114.3076
2024-02-29EA Bridgeway Omni Small-Cap Value ETF0.20620.034627651350.2156
2024-02-28iShares Micro-Cap ETF0.17620.0377536263480.6532
2023-09-30BlackRock Extended Mkt Composite0.12180.00113708200
2023-12-31BlackRock Extended Equity Market K0.10630.000932351-65-0.2005
2023-12-31Fidelity Total Market Index0.10190.00023100300
2023-12-31Fidelity Series Total Market Index0.07150.00012176000
2023-09-30Bridgeway Omni Small-Cap Value N0.06570.00722000000
2023-12-31Bridgeway Omni Small-Cap Value0.06570.00622000000
2023-12-31NT Ext Equity Mkt Idx Fd - L0.06290.00131914900
2023-12-31Northern Trust Extended Eq Market Idx0.06290.00131914900
2023-12-31T. Rowe Price U.S. Equities Tr0.05780.00081760000
2023-12-31Fidelity Nasdaq Composite Index0.05060.00041539500
2024-01-31DFA US Micro Cap I0.05010.0011523500
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.04480.00091362300
2024-02-29Fidelity® Small Cap Enhanced Index0.04190.015812740-219-1.6899
2024-01-31Vanguard Balanced Index Inv0.03840.00011167900
Total 4.71230.47751434238+18059+1.3%

3.3. Insider Transactions

Insiders are holding 36.023% of the shares of XBiotech Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-10-14John SimardSELL2112512.9
2021-10-12John SimardSELL1800012.77
2021-10-07John SimardSELL3928612.45
2021-10-05John SimardSELL1421812.66
2021-10-01John SimardSELL1968413.23
2021-09-29John SimardSELL1639613.41
2021-09-27John SimardSELL2989014.81
2021-09-24John SimardSELL1141814.49
2021-09-22John SimardSELL1966915.14
2021-09-20John SimardSELL1347115.06
2021-07-14John SimardSELL5000018.15

4. Summary

4.1. Key Performance Indicators

The key performance indicators of XBiotech Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.125-0.177+41%-0.238+90%0.302-141%0.167-175%
Book Value Per Share--7.1877.450-4%8.264-13%8.638-17%5.201+38%
Current Ratio--33.06944.635-26%57.389-42%48.476-32%29.512+12%
Debt To Asset Ratio--0.0370.029+29%0.027+39%0.030+22%0.048-23%
Debt To Equity Ratio--0.0380.030+30%0.027+40%0.032+21%0.052-26%
Dividend Per Share----0%-0%0.616-100%0.300-100%
Eps---0.152-0.202+32%-0.270+77%0.784-119%0.245-162%
Free Cash Flow Per Share---0.117-0.157+34%-0.127+9%-0.070-40%-0.163+40%
Free Cash Flow To Equity Per Share---0.117-0.081-30%-0.127+9%-0.675+479%-0.319+174%
Gross Profit Margin--0.9060.977-7%1.000-9%0.995-9%0.998-9%
Intrinsic Value_10Y_max--2.287--------
Intrinsic Value_10Y_min---6.356--------
Intrinsic Value_1Y_max--0.328--------
Intrinsic Value_1Y_min---0.655--------
Intrinsic Value_3Y_max--0.910--------
Intrinsic Value_3Y_min---1.964--------
Intrinsic Value_5Y_max--1.401--------
Intrinsic Value_5Y_min---3.259--------
Market Cap247565817.000+51%121803600.000133298814.750-9%162912315.000-25%329485619.750-63%281642493.301-57%
Net Profit Margin----0%-9.1530%-2.0730%-1.0110%
Operating Margin----0%-13.6510%-3.1260%-1.5250%
Operating Ratio----0%14.651-100%3.704-100%1.807-100%
Pb Ratio1.131+51%0.5570.588-5%0.639-13%1.913-71%2.506-78%
Pe Ratio-13.353-103%-6.570-5.721-13%-6.598+0%-360.564+5388%-179.282+2629%
Price Per Share8.130+51%4.0004.378-9%5.350-25%10.176-61%8.614-54%
Price To Free Cash Flow Ratio-17.444-103%-8.583-9.896+15%-3.277-62%-6.870-20%-6.537-24%
Price To Total Gains Ratio-64.927-103%-31.944-26.160-18%-30.157-6%28.842-211%5.567-674%
Quick Ratio--32.94452.067-37%65.096-49%49.850-34%29.959+10%
Return On Assets---0.020-0.026+29%-0.032+56%0.010-305%-0.073+260%
Return On Equity---0.021-0.027+28%-0.033+54%0.012-276%-0.079+274%
Total Gains Per Share---0.125-0.177+41%-0.238+90%0.918-114%0.468-127%
Usd Book Value--218846000.000226868250.000-4%251641500.000-13%273516100.000-20%166276024.390+32%
Usd Book Value Change Per Share---0.125-0.177+41%-0.238+90%0.302-141%0.167-175%
Usd Book Value Per Share--7.1877.450-4%8.264-13%8.638-17%5.201+38%
Usd Dividend Per Share----0%-0%0.616-100%0.300-100%
Usd Eps---0.152-0.202+32%-0.270+77%0.784-119%0.245-162%
Usd Free Cash Flow---3548000.000-4771750.000+34%-3852250.000+9%-2796300.000-21%-5644536.585+59%
Usd Free Cash Flow Per Share---0.117-0.157+34%-0.127+9%-0.070-40%-0.163+40%
Usd Free Cash Flow To Equity Per Share---0.117-0.081-30%-0.127+9%-0.675+479%-0.319+174%
Usd Market Cap247565817.000+51%121803600.000133298814.750-9%162912315.000-25%329485619.750-63%281642493.301-57%
Usd Price Per Share8.130+51%4.0004.378-9%5.350-25%10.176-61%8.614-54%
Usd Profit---4635000.000-6139250.000+32%-8225000.000+77%29126800.000-116%9987658.537-146%
Usd Revenue----0%1002500.000-100%3320050.000-100%1619536.585-100%
Usd Total Gains Per Share---0.125-0.177+41%-0.238+90%0.918-114%0.468-127%
 EOD+5 -3MRQTTM+15 -15YOY+18 -145Y+6 -2810Y+18 -16

4.2. Fundamental Score

Let's check the fundamental score of XBiotech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13.353
Price to Book Ratio (EOD)Between0-11.131
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than132.944
Current Ratio (MRQ)Greater than133.069
Debt to Asset Ratio (MRQ)Less than10.037
Debt to Equity Ratio (MRQ)Less than10.038
Return on Equity (MRQ)Greater than0.15-0.021
Return on Assets (MRQ)Greater than0.05-0.020
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of XBiotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose8.200
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets227,243
Total Liabilities8,397
Total Stockholder Equity218,846
 As reported
Total Liabilities 8,397
Total Stockholder Equity+ 218,846
Total Assets = 227,243

Assets

Total Assets227,243
Total Current Assets201,718
Long-term Assets25,525
Total Current Assets
Cash And Cash Equivalents 200,023
Net Receivables 935
Other Current Assets 760
Total Current Assets  (as reported)201,718
Total Current Assets  (calculated)201,718
+/-0
Long-term Assets
Property Plant Equipment 24,897
Long-term Assets  (as reported)25,525
Long-term Assets  (calculated)24,897
+/- 628

Liabilities & Shareholders' Equity

Total Current Liabilities6,100
Long-term Liabilities2,297
Total Stockholder Equity218,846
Total Current Liabilities
Accounts payable 2,516
Other Current Liabilities 3,584
Total Current Liabilities  (as reported)6,100
Total Current Liabilities  (calculated)6,100
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)2,297
Long-term Liabilities  (calculated)0
+/- 2,297
Total Stockholder Equity
Common Stock271,152
Retained Earnings -52,306
Total Stockholder Equity (as reported)218,846
Total Stockholder Equity (calculated)218,846
+/-0
Other
Capital Stock271,152
Cash and Short Term Investments 200,023
Common Stock Shares Outstanding 30,437
Liabilities and Stockholders Equity 227,243
Net Debt -200,023
Net Invested Capital 218,846
Net Working Capital 195,618
Property Plant and Equipment Gross 43,136



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-11-022017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
11,073
0
0
19,661
62,177
58,688
126,847
119,047
109,358
101,262
93,201
78,292
67,050
87,616
77,841
70,671
70,671
62,972
58,860
54,290
49,244
44,345
39,824
71,875
66,643
816,877
358,373
358,762
353,393
353,744
355,940
353,956
279,519
275,177
270,803
266,462
250,834
246,103
242,121
235,136
229,599
227,243
227,243229,599235,136242,121246,103250,834266,462270,803275,177279,519353,956355,940353,744353,393358,762358,373816,87766,64371,87539,82444,34549,24454,29058,86062,97270,67170,67177,84187,61667,05078,29293,201101,262109,358119,047126,84758,68862,17719,6610011,073
   > Total Current Assets 
7,693
0
0
15,871
58,064
53,765
120,353
107,587
93,041
79,839
66,328
48,841
36,930
57,085
47,301
40,289
40,289
33,332
29,749
25,766
21,306
17,016
12,982
45,599
40,911
716,263
257,896
258,389
251,685
325,875
327,899
324,863
250,237
246,870
242,980
238,764
223,427
219,843
216,284
209,512
204,402
201,718
201,718204,402209,512216,284219,843223,427238,764242,980246,870250,237324,863327,899325,875251,685258,389257,896716,26340,91145,59912,98217,01621,30625,76629,74933,33240,28940,28947,30157,08536,93048,84166,32879,83993,041107,587120,35353,76558,06415,871007,693
       Cash And Cash Equivalents 
7,244
0
0
15,497
57,329
52,236
117,382
105,680
91,051
78,225
64,798
46,793
34,324
54,632
45,949
38,977
38,977
31,768
28,416
24,849
20,849
15,823
12,019
44,921
40,338
714,594
241,540
229,703
238,431
237,366
239,879
315,258
238,877
236,983
231,821
225,793
160,568
157,306
152,484
143,391
202,191
200,023
200,023202,191143,391152,484157,306160,568225,793231,821236,983238,877315,258239,879237,366238,431229,703241,540714,59440,33844,92112,01915,82320,84924,84928,41631,76838,97738,97745,94954,63234,32446,79364,79878,22591,051105,680117,38252,23657,32915,497007,244
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,000
0
75,058
0
0
0
0
0
0
0
59,532
60,172
60,178
61,380
0
0
0061,38060,17860,17259,532000000075,058075,00000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,474
25,654
12,172
10,687
5,036
8,134
10,441
8,953
10,527
12,426
2,706
1,764
2,919
3,794
1,332
935
9351,3323,7942,9191,7642,70612,42610,5278,95310,4418,1345,03610,68712,17225,65413,47400000000000000000000000000
       Other Current Assets 
449
0
0
374
735
1,529
2,971
1,907
1,990
1,614
1,530
2,048
2,606
2,453
1,352
1,312
1,564
1,564
1,333
917
457
1,193
963
678
573
1,669
2,882
3,032
1,082
77,822
82,984
1,471
919
9,887
632
545
62,859
601
703
947
879
760
76087994770360162,8595456329,8879191,47182,98477,8221,0823,0322,8821,6695736789631,1934579171,3331,5641,5641,3121,3522,4532,6062,0481,5301,6141,9901,9072,9711,52973537400449
   > Long-term Assets 
3,380
0
0
3,790
4,113
4,923
6,494
11,460
16,317
21,423
26,873
29,451
30,120
30,531
30,540
30,382
29,640
29,640
29,111
28,524
27,938
27,329
26,842
26,276
25,732
100,614
100,477
100,373
101,708
27,869
28,041
29,093
29,282
28,308
27,823
27,698
27,407
26,260
25,836
25,624
25,197
25,525
25,52525,19725,62425,83626,26027,40727,69827,82328,30829,28229,09328,04127,869101,708100,373100,477100,61425,73226,27626,84227,32927,93828,52429,11129,64029,64030,38230,54030,53130,12029,45126,87321,42316,31711,4606,4944,9234,1133,790003,380
       Property Plant Equipment 
3,380
0
0
3,790
4,113
4,923
6,494
11,460
16,317
21,423
26,873
29,451
30,120
30,531
30,540
30,382
30,382
29,640
29,111
28,524
27,938
27,329
26,842
26,276
25,732
25,171
25,034
24,882
26,207
27,336
27,508
28,451
28,640
28,308
27,823
27,276
26,635
26,260
25,836
25,624
25,197
24,897
24,89725,19725,62425,83626,26026,63527,27627,82328,30828,64028,45127,50827,33626,20724,88225,03425,17125,73226,27626,84227,32927,93828,52429,11129,64030,38230,38230,54030,53130,12029,45126,87321,42316,31711,4606,4944,9234,1133,790003,380
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,443
75,443
75,491
75,501
533
533
642
642
-1
0
422
772
0
1
0
0
0
000107724220-164264253353375,50175,49175,44375,4430000000000000000000000000
> Total Liabilities 
845
0
0
2,443
3,147
3,828
2,872
4,970
6,308
6,583
10,397
6,663
7,986
5,346
4,685
3,522
3,522
2,810
2,450
2,768
2,307
2,947
2,841
2,462
2,021
61,246
11,291
15,192
7,254
5,105
3,842
5,392
5,362
5,792
5,243
10,667
6,025
5,701
5,216
6,073
6,940
8,397
8,3976,9406,0735,2165,7016,02510,6675,2435,7925,3625,3923,8425,1057,25415,19211,29161,2462,0212,4622,8412,9472,3072,7682,4502,8103,5223,5224,6855,3467,9866,66310,3976,5836,3084,9702,8723,8283,1472,44300845
   > Total Current Liabilities 
845
0
0
2,443
3,147
3,826
2,865
4,958
6,291
6,563
10,376
6,641
7,963
5,323
4,663
3,502
3,502
2,792
2,434
2,756
2,300
2,944
2,841
2,462
2,021
60,190
10,235
14,136
6,198
3,984
2,721
3,891
3,861
3,453
2,891
8,235
3,578
4,066
3,618
4,450
5,294
6,100
6,1005,2944,4503,6184,0663,5788,2352,8913,4533,8613,8912,7213,9846,19814,13610,23560,1902,0212,4622,8412,9442,3002,7562,4342,7923,5023,5024,6635,3237,9636,64110,3766,5636,2914,9582,8653,8263,1472,44300845
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
49,361
1,715
2,565
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000002,5651,71549,3610000000000000000000000000
       Accounts payable 
561
0
0
1,218
1,629
2,915
2,285
3,964
4,825
4,846
8,494
4,465
4,431
2,697
3,385
2,225
2,792
1,730
1,160
1,455
878
1,653
1,861
1,550
1,061
2,149
5,649
5,240
3,870
2,491
1,238
1,491
1,012
2,069
1,323
2,454
1,376
2,408
1,357
1,816
1,468
2,516
2,5161,4681,8161,3572,4081,3762,4541,3232,0691,0121,4911,2382,4913,8705,2405,6492,1491,0611,5501,8611,6538781,4551,1601,7302,7922,2253,3852,6974,4314,4658,4944,8464,8253,9642,2852,9151,6291,21800561
       Other Current Liabilities 
284
0
0
1,225
1,518
911
580
994
1,466
1,717
1,882
2,176
3,532
2,626
1,278
1,277
18
1,062
1,274
1,301
1,422
1,291
980
912
960
4,180
1,371
4,831
2,328
1,493
1,483
2,400
2,849
1,384
1,568
5,781
2,202
1,658
2,261
2,634
3,826
3,584
3,5843,8262,6342,2611,6582,2025,7811,5681,3842,8492,4001,4831,4932,3284,8311,3714,1809609129801,2911,4221,3011,2741,062181,2771,2782,6263,5322,1761,8821,7171,4669945809111,5181,22500284
   > Long-term Liabilities 
0
0
0
0
0
2
7
12
17
20
21
22
23
23
22
20
0
18
16
12
7
3
3
0
0
1,056
1,056
1,056
1,056
1,121
1,121
1,501
1,501
2,339
2,352
2,432
2,447
1,635
1,598
1,623
1,646
2,297
2,2971,6461,6231,5981,6352,4472,4322,3522,3391,5011,5011,1211,1211,0561,0561,0561,0560033712161802022232322212017127200000
       Other Liabilities 
0
0
0
0
0
2
7
12
17
20
21
22
23
23
22
20
0
18
16
12
7
3
0
0
0
1,056
1,056
1,056
1,056
1,121
1,121
1,501
1,501
2,339
2,352
2,432
2,447
1,635
0
1,623
0
0
001,62301,6352,4472,4322,3522,3391,5011,5011,1211,1211,0561,0561,0561,0560003712161802022232322212017127200000
       Deferred Long Term Liability 
0
0
0
0
17
2
7
0
17
20
0
0
0
0
22
20
0
0
0
12
0
0
0
0
0
0
0
0
0
0
0
108
108
0
0
0
0
0
0
0
0
0
0000000001081080000000000012000202200002017072170000
> Total Stockholder Equity
10,228
0
0
17,218
59,030
54,860
123,975
114,077
103,050
94,679
82,804
71,629
59,064
82,270
73,156
67,149
60,162
60,162
56,410
51,522
46,937
41,398
36,983
69,413
64,622
755,631
347,082
343,570
346,139
348,639
352,098
348,564
274,157
269,385
265,560
255,795
244,809
240,402
236,905
229,063
222,659
218,846
218,846222,659229,063236,905240,402244,809255,795265,560269,385274,157348,564352,098348,639346,139343,570347,082755,63164,62269,41336,98341,39846,93751,52256,41060,16260,16267,14973,15682,27059,06471,62982,80494,679103,050114,077123,97554,86059,03017,2180010,228
   Common Stock
81,807
0
0
104,619
152,351
156,393
231,935
232,850
233,902
235,751
237,523
238,808
242,419
276,079
276,589
277,078
277,492
277,492
277,803
278,441
278,879
279,353
280,664
319,045
320,130
324,808
242,942
246,395
251,781
249,805
255,513
256,779
260,876
262,263
263,711
265,159
266,287
267,325
268,030
268,930
269,890
271,152
271,152269,890268,930268,030267,325266,287265,159263,711262,263260,876256,779255,513249,805251,781246,395242,942324,808320,130319,045280,664279,353278,879278,441277,803277,492277,492277,078276,589276,079242,419238,808237,523235,751233,902232,850231,935156,393152,351104,6190081,807
   Retained Earnings 
-71,444
0
0
-87,279
-93,168
-101,282
-108,026
-118,762
-130,651
-140,908
-154,529
-167,013
-183,412
-193,975
-203,107
-209,313
-209,313
-216,562
-220,631
-226,538
-231,589
-237,700
-243,564
-249,416
-255,566
430,929
104,156
97,312
94,786
97,568
95,000
89,882
11,618
5,151
-244
-11,888
-24,546
-27,749
-31,565
-40,307
-47,671
-52,306
-52,306-47,671-40,307-31,565-27,749-24,546-11,888-2445,15111,61889,88295,00097,56894,78697,312104,156430,929-255,566-249,416-243,564-237,700-231,589-226,538-220,631-216,562-209,313-209,313-203,107-193,975-183,412-167,013-154,529-140,908-130,651-118,762-108,026-101,282-93,168-87,27900-71,444
   Accumulated Other Comprehensive Income 
-135
0
0
-122
-153
-251
66
-11
-201
-164
-190
-166
57
166
-326
-616
-616
-768
-762
-381
-353
-255
-117
-216
58
-106
-16
-137
-428
1,266
1,585
1,903
1,663
1,971
2,093
2,524
3,068
826
440
440
440
0
04404404408263,0682,5242,0931,9711,6631,9031,5851,266-428-137-16-10658-216-117-255-353-381-762-768-616-616-32616657-166-190-164-201-1166-251-153-12200-135
   Capital Surplus 000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue300
Cost of Revenue-1,744
Gross Profit-1,744-1,444
 
Operating Income (+$)
Gross Profit-1,744
Operating Expense-35,766
Operating Income-37,510-37,510
 
Operating Expense (+$)
Research Development32,848
Selling General Administrative4,662
Selling And Marketing Expenses-1,744
Operating Expense35,76635,766
 
Net Interest Income (+$)
Interest Income10,290
Interest Expense-0
Other Finance Cost-0
Net Interest Income10,290
 
Pretax Income (+$)
Operating Income-37,510
Net Interest Income10,290
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-24,313-50,707
EBIT - interestExpense = -37,510
-24,313
-24,557
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-37,510-24,313
Earnings Before Interest and Taxes (EBITDA)-35,766
 
After tax Income (+$)
Income Before Tax-24,313
Tax Provision-921
Net Income From Continuing Ops-23,125-25,234
Net Income-24,557
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses37,510
Total Other Income/Expenses Net13,197-10,290
 

Technical Analysis of Xbiotech
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xbiotech. The general trend of Xbiotech is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xbiotech's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of XBiotech Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.1.

The bearish price targets are: 7.24 > 6.568 > 6.12.

Tweet this
XBiotech Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of XBiotech Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

XBiotech Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of XBiotech Inc.

XBiotech Inc Daily Moving Average Convergence/Divergence (MACD) ChartXBiotech Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of XBiotech Inc. The current adx is .

XBiotech Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of XBiotech Inc.

XBiotech Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of XBiotech Inc.

XBiotech Inc Daily Relative Strength Index (RSI) ChartXBiotech Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of XBiotech Inc.

XBiotech Inc Daily Stochastic Oscillator ChartXBiotech Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of XBiotech Inc.

XBiotech Inc Daily Commodity Channel Index (CCI) ChartXBiotech Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of XBiotech Inc.

XBiotech Inc Daily Chande Momentum Oscillator (CMO) ChartXBiotech Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of XBiotech Inc.

XBiotech Inc Daily Williams %R ChartXBiotech Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of XBiotech Inc.

XBiotech Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of XBiotech Inc.

XBiotech Inc Daily Average True Range (ATR) ChartXBiotech Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of XBiotech Inc.

XBiotech Inc Daily On-Balance Volume (OBV) ChartXBiotech Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of XBiotech Inc.

XBiotech Inc Daily Money Flow Index (MFI) ChartXBiotech Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for XBiotech Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

XBiotech Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of XBiotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose8.200
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xbiotech with someone you think should read this too:
  • Are you bullish or bearish on Xbiotech? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xbiotech? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about XBiotech Inc

I send you an email if I find something interesting about XBiotech Inc.


Comments

How you think about this?

Leave a comment

Stay informed about XBiotech Inc.

Receive notifications about XBiotech Inc in your mailbox!